9436results about "Skeletal disorder" patented technology

The invention provides a probiotics plant solid beverage for treating hyperuricemia and gout. The solid beverage is prepared by mixing freeze-dried probiotics powder and plant extract with the addition of proper auxiliary materials. The solid beverage comprises the following components: the plant extract, the auxiliary materials and the probiotics, with the sum of the mass percentage of each component being 100%. The plant extract comprises celery seed powder, sophora flower bud powder and platycodon root powder. The invention has an obvious effect on lowering uric acid and relieving gout.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

The present application relates to animal bifidobacterium lactis Ca360 and its application. The present application also provides the application of animal bifidobacterium lactis in promoting the absorption and transport of minerals, improving osteoporosis, iron deficiency anemia and zinc deficiency. The animal bifidobacterium lactis of the present application can promote the absorption and transport of minerals, improve osteoporosis, iron deficiency anemia and zinc deficiency.

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.

The invention discloses a peptide with a bone strengthening effect as well as a preparation method and application thereof, and relates to the field of biology. The casein is used as a raw material, the high-activity calcium ion chelating peptide and the directional preparation technology thereof are provided, the technology has the advantages of being high in efficiency, low in cost, easy to operate, good in stability and the like, the high-activity calcium ion chelating peptide can be prepared on a large scale, the utilization value of the casein is improved, and a new way is provided for development of functional natural calcium supplement products.

The present application relates to chondrocyte compositions and kits comprising morselized cartilage tissue particles and a biodegradable matrix. Applications and methods of using the chondrocyte composition for cartilage grafts, repairing cartilage injuries and defects, and joint repair are provided.

The preservation number of the bacterial strain is CGMCC (China General Microbiological Culture Collection Center) NO.33629, the preservation date of the bacterial strain is February 24, 2025, the preservation classification of the bacterial strain is Lactobacillus sakei, and the preservation unit of the bacterial strain is China General Microbiological Culture Collection Center. The strain provided by the invention can reduce the concentration of blood uric acid, relieve kidney inflammation caused by hyperuricemia, improve the protein level of a kidney uric acid excretion channel and reduce the expression level of uric acid resorption protein.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.

The invention provides a compound of a GLP-1R agonist or modulator with a structure as shown in a formula (I).

The invention discloses camel milk polypeptide with xanthine oxidase inhibitory activity and application thereof.The camel milk polypeptide is prepared by taking fresh camel milk as a raw material, conducting low-temperature centrifugation to remove fat, conducting triple enzymolysis through papain, pepsin and trypsin to obtain enzymatic hydrolysate, enabling the enzymatic hydrolysate to pass through an ultrafiltration membrane (the molecular weight cutoff is 10 kDa) to obtain filtrate, and conducting freeze-drying to obtain the camel milk polypeptide. The compound has xanthine oxidase inhibitory activity. The invention also discloses a small molecule polypeptide with xanthine oxidase inhibitory activity. The filtered solution is screened and combined with polypeptides by adopting a xanthine oxidase affinity ultrafiltration method, the activity of the polypeptides is verified through molecular docking and in-vitro enzyme inhibition, four small-molecule polypeptides with xanthine oxidase inhibitory activity are obtained, the sequence of the small-molecule polypeptides is shown as any one of SEQ ID NO.1-4, and the small-molecule polypeptides can be used for preparing drugs with the effect of inhibiting the uric acid level.

The invention provides a benzofuranone compound as well as a pharmaceutical composition and application thereof, and relates to the technical field of medicines. The benzofuranone compound is a compound as shown in a formula I, a stereoisomer thereof, a tautomer thereof, a crystalline hydrate thereof, a solvate thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof. The benzofuranone compound and the pharmaceutical composition and the pharmaceutical preparation prepared from the benzofuranone compound can prevent or treat organ injury diseases, and have good treatment effects in kidney injury, liver injury, lung injury, brain injury and heart injury.

The invention relates to the technical field of biological medicine, in particular to a ferroptosis inhibition type phospholipid-like material and application thereof. The ferroptosis inhibition type phospholipid-like material is one of the following structural general formulas (1)-(5). The biomimetic phospholipid-like ferroptosis inhibitor has a long retention characteristic in main positions (cell membranes, endoplasmic reticulum and other organelle membranes) of cell ferroptosis, so that the ferroptosis inhibition efficiency is remarkably improved. The novel phospholipid-like material not only can be used as an active drug molecule, but also can be used as a pharmaceutic adjuvant for constructing drug delivery carriers such as lipidosome and micelle and implant coatings, and is suitable for various administration routes such as oral administration, injection and local administration. The novel biomimetic ferroptosis inhibitor can efficiently relieve cell ferroptosis and has a wide application prospect in the field of treating or retarding ferroptosis-related diseases.

The invention discloses an antler bone strengthening peptide for promoting bone repair as well as a screening method and application thereof, and belongs to the technical field of traditional Chinese medicinal material polypeptides. And the antler bone strengthening peptide is one of G40, G44 and G45. Grinding and crushing the antler, homogenizing the lysate, performing ultrasonic centrifugation, precipitating protein with methanol, centrifuging and discarding the supernatant; extracting, desalting, and freeze-drying to obtain a antler polypeptide extract; liquid chromatography-mass spectrometry detection, Peaks 8 search software and De Novo method analysis are adopted, according to the conditions that ALC is larger than or equal to 95%, local context is larger than or equal to 95%, Area is larger than or equal to 1000000 and an NCBI database, free polypeptide is obtained through comparison, the biological activity probability, the peptide fragment toxicity and the sensitization of the peptide fragment are predicted, and candidate polypeptide is obtained; synthesizing candidate polypeptides by a solid-phase synthesis method; the influence of the candidate polypeptide on osteoblast proliferation is evaluated, and the antler bone strengthening peptide is screened out. The antler bone strengthening peptide promotes osteoblast proliferation, and reveals a potential bone repair mechanism of the antler bone strengthening peptide.

The invention relates to the technical field of functional product preparation, and provides a rhizoma polygonati and saussurea involucrata bone marrow peptide tablet as well as a preparation method and application thereof. The rhizoma polygonati and saussurea involucrata bone marrow peptide tablet is prepared from the following components: collagen peptide powder, L-isoleucine, a compound nutrient supplement, rhizoma polygonati, sorbitol, yak bone marrow peptide powder, fructus phyllanthi, fructus alpiniae oxyphyllae, mulberry powder, a saussurea involucrata culture and magnesium stearate. All the components of the rhizoma polygonati and saussurea involucrata bone marrow peptide tablet disclosed by the invention have a synergistic effect, so that the effects of conditioning sub-health, maintaining joints and assisting in treating diseases can be achieved.

The invention discloses bifidobacterium longum subsp.infantis capable of promoting bone growth and a metagen thereof, and belongs to the technical field of biology. The bifidobacterium longum subsp. Infantis CCFM1445 provided by the invention can promote the increase of bone volume fraction, femoral bone trabecula thickness and far-end growth plate thickness of mammals in a growth period, reduce the levels of serum bone resorption markers I-type collagen amino-terminal peptide and tartrate-resistant acid phosphatase, improve the levels of serum bone alkaline phosphatase and parathyroid hormone, and improve the clinical application value of the bifidobacterium longum subsp. Infantis CCFM1445. And the relative abundance of the other bacteria in the intestinal flora and the levels of creatine and indole-3-lactic acid are increased. The thermally inactivated bifidobacterium longum subsp. Infantis CCFM1445 can promote the increase of the volume fraction of femoral bones and the number of bone trabecula of malnourished mice and improve the N-terminal propeptide level of serum I-type procollagen. Therefore, the medicine or health care product prepared from the bifidobacterium longum subsp. Infantis CCFM1445 can be used for assisting in regulating bone metabolism and bone mass, and has a wide market prospect.

Provided in the present invention are compounds as VAV1 degradation agents and the use thereof. Specifically provided are compounds represented by formula (II), and tautomers, stereoisomers, pharmaceutically acceptable salts or prodrugs thereof. The compounds provided by the present invention have good efficacy, and can be used for preparing drugs for treating or preventing VAV1-related diseases.

The invention belongs to the technical field of biomedical anti-inflammatory gels, and discloses a renewable boundary lubrication natural polyphenol anti-inflammatory hydrogel and a preparation method and application thereof.The hydrogel is of a hydrophilic viscoelastic sea island structure, gallic acid grafted gelatin blended with hyaluronic acid serves as a base material, celecoxib lipidosome is entrapped in the hydrogel, and the hydrogel is prepared from natural polyphenols, an articular cavity is injected through an enzyme crosslinking technology to form gel, hyaluronic acid and lipidosome form a hydrated lubricating layer on a cartilage-gel interface, and after the interface is abraded, internal lipidosome and hyaluronic acid are exposed to supplement lubrication so as to form sustainable lubrication; the liposome responds to friction shear crushing to release celecoxib and cooperates with gallic acid at an interface to resist inflammation progress and repair cartilage, the injectable hydrogel is developed based on gallic acid, hyaluronic acid, gelatin and celecoxib liposome to treat early osteoarthritis, mechanical lubrication and inflammation resistance are combined, and the preparation method has the advantages that the preparation method is simple, the preparation cost is low, and the application prospect is wide. The problems of large-dose toxicity, short lubrication period and the like caused by independent treatment are effectively solved, and the preparation has important clinical application significance.

The invention relates to the technical field of biomedicine, in particular to stem cell exosome-loaded bi-crosslinked hydrogel as well as preparation and application thereof, and the bi-crosslinked hydrogel comprises the following components in parts by weight: 50-90 parts of a matrix polymer; 0.1 to 5 parts of an active load; 1 to 10 parts of cyclodextrin; 5 to 20 parts of modified chitosan; 0.01 to 1 part of a photoinitiator; and 0.01 to 0.5 part of growth factors. Through double-network design of physical / chemical primary cross-linking and photo-initiation secondary cross-linking, the bottleneck that the mechanical property and the machinability of the traditional single cross-linking hydrogel are difficult to consider at the same time is overcome; meanwhile, the human umbilical vein endothelial cell exosome is introduced, and efficient loading, uniform dispersion and degradation coupling slow release of the exosome are realized by virtue of beta-cyclodextrin inclusion and a double-crosslinking network. Therefore, the problems of mechanics, degradation, cross-linking speed or tissue adhesion of cross-linked hydrogel in the prior art are solved.

The invention discloses a lactobacillus rhamnosus capable of improving joint inflammation and promoting bone health, a metagen and application of the lactobacillus rhamnosus, the lactobacillus rhamnosus is lactobacillus rhamnosus BN02, the lactobacillus rhamnosus is preserved in China General Microbiological Culture Collection Center on November 27, 2023, and the preservation number is CGMCC No.29133. The lactobacillus rhamnosus can be used for improving joint inflammation and promoting bone health. The lactobacillus rhamnosus BN02 can reduce the number of gram-negative bacteria in intestinal tracts of arthritis patients, increase the synthesis amount of bone collagen, and is beneficial to promoting absorption of vitamin C by the intestinal tracts, improving joint inflammation and promoting bone health.

The invention discloses an endogenous anti-aging composition based on an internal and external synergistic mechanism and a preparation method of the endogenous anti-aging composition. The endogenous anti-aging composition based on the internal and external synergistic mechanism is prepared from the following components in parts by mass: 100 to 200 parts of alpha-ketoglutarate calcium; 100 to 200 parts of an olive leaf extract; 10 to 20 parts of nicotinic acid; 10 to 20 parts of pyrroloquinoline quinone; 20 to 60 parts of pomegranate extract; and 10 to 30 parts of coenzyme Q10. The composition and the preparation method thereof have the beneficial effects that the composition capable of integrally improving the aging state of women from multiple dimensions and the preparation method of the composition are provided.

The invention relates to the technical field of medicines, in particular to a construction method and application of a photothermal conversion platform for treating osteoarthritis by regulating synovial macrophage polarization. According to the present invention, the M2 membrane-structured black phosphorus selenium carbon body (M2-BPSeC) photo-thermal nano-platform is innovatively provided, the triple functions of bionic targeting delivery, precise thermal control intervention and immune microenvironment remodeling are integrated, and the excellent synergistic treatment effect is represented in the in-vitro cell model and the OA animal model. The technology breaks through the technical bottleneck that traditional treatment is insufficient in targeting and single in intervention dimension, precise functional coupling of the physical thermal effect and immunoregulation is achieved for the first time, and a brand new strategy of targeting-temperature control-immunity integration is provided for osteoarthritis treatment. The efficient and controllable preparation process and the remarkable multi-dimensional treatment effect open up a new path for cartilage regeneration and immune balance regulation and control.